• 1. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 2. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 3. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 4. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 5. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782

Introduction to (6-methyl-1H-indol-3-yl)methanamine (CAS No. 940304-82-5)

(6-methyl-1H-indol-3-yl)methanamine, with the CAS number 940304-82-5, is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structural features, which include a 6-methyl-substituted indole ring and a methanamine functional group. These structural elements contribute to its potential biological activities and make it a valuable candidate for various applications in drug discovery and development.

The chemical structure of (6-methyl-1H-indol-3-yl)methanamine is represented by the formula C₁₀H₁₃N₂. The indole ring, a common motif in many biologically active molecules, is known for its diverse pharmacological properties, including anti-inflammatory, anti-cancer, and neuroprotective effects. The presence of the 6-methyl substituent can influence the compound's lipophilicity and metabolic stability, which are crucial factors in drug design.

Recent studies have explored the potential therapeutic applications of (6-methyl-1H-indol-3-yl)methanamine. One notable area of research is its activity as a serotonin receptor modulator. Serotonin receptors play a pivotal role in regulating mood, sleep, and appetite, making them important targets for the treatment of various neurological disorders such as depression, anxiety, and schizophrenia. In vitro studies have shown that (6-methyl-1H-indol-3-yl)methanamine exhibits selective binding to specific serotonin receptor subtypes, suggesting its potential as a lead compound for developing novel antidepressants or anxiolytics.

Beyond its serotonin receptor modulating properties, (6-methyl-1H-indol-3-yl)methanamine has also been investigated for its anti-inflammatory effects. Inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease are characterized by chronic inflammation and tissue damage. Preclinical studies have demonstrated that (6-methyl-1H-indol-3-yl)methanamine can inhibit the production of pro-inflammatory cytokines and reduce oxidative stress, making it a promising candidate for the development of anti-inflammatory drugs.

The pharmacokinetic profile of (6-methyl-1H-indol-3-yl)methanamine is another important aspect of its evaluation. Understanding how the compound is absorbed, distributed, metabolized, and excreted (ADME) in the body is crucial for optimizing its therapeutic potential. Studies have shown that (6-methyl-1H-indol-3-yl)methanamine has favorable oral bioavailability and a reasonable half-life, which are desirable properties for an orally administered drug.

In addition to its therapeutic applications, (6-methyl-1H-indol-3-yl)methanamine has been used as a building block in the synthesis of more complex molecules. Its versatile reactivity allows chemists to introduce various functional groups or modify existing ones, leading to the creation of novel compounds with enhanced biological activities. This synthetic flexibility makes it an attractive starting material for combinatorial chemistry approaches in drug discovery.

The safety profile of (6-methyl-1H-indol-3-yl)methanamine is also an important consideration. Preclinical toxicity studies have indicated that it has a favorable safety margin at therapeutic doses. However, further clinical trials are necessary to fully assess its safety and efficacy in human subjects. These trials will provide valuable data on dosing regimens, potential side effects, and long-term safety profiles.

In conclusion, (6-methyl-1H-indol-3-yl)methanamine (CAS No. 940304-82-5) is a promising compound with diverse biological activities and potential therapeutic applications. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further research and development in the fields of medicinal chemistry and pharmaceutical sciences. As ongoing studies continue to uncover new insights into its mechanisms of action and therapeutic potential, it is likely that this compound will play an increasingly important role in the discovery and development of novel drugs.

• 35998-04-0(6-Methylgramine)
• 408356-52-5(1H-indol-7-ylmethanamine)
• 30218-58-7(N,N-Dimethyl-1-(5-methyl-1H-indol-3-yl)methanamine)
• 887596-96-5((5-methyl-1H-indol-3-yl)methanamine)
• 296775-93-4(3-(AMINOMETHYL)INDOLE OXALATE)
• 164119-81-7(N,N-Dimethyl-1-(4-methyl-1H-indol-3-yl)methanamine)
• 87-52-5(Gramine)
• 22259-53-6(1H-indol-3-ylmethanamine)
• 57506-64-6(N-(3-Indolylmethyl)benzylamine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)